Drugs Made In America Acquisition Corp. (DMAAR) Interest & Investment Income (2025 - 2026)
Drugs Made In America Acquisition's (DMAAR) quarterly Interest & Investment Income came in at $1.9 million in Q2 2026, down 23.0% on a YoY basis from $2.4 million in Q2 2025, and down 19.05% quarter-over-quarter from $2.3 million in Q4 2025.
Powered by 
Analysis
Drugs Made In America Acquisition Corp. (DMAAR) Interest & Investment Income (2025 - 2026) Analysis & Trends
Drugs Made In America Acquisition (DMAAR) has reported Interest & Investment Income for 2 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest & Investment Income fell 23.0% year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2026 stood at $9.0 million (changed N/A YoY), and the FY2025 full-year result was $8.8 million, changed N/A from the prior year.
- Interest & Investment Income fell to $1.9 million in Q2 2026 per DMAAR's latest filing, from $2.3 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2.4 million in Q3 2025 and bottomed at $1.6 million in Q1 2025.
Peer Set
Peer Comparison
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.86 Mn |
| Dec 31, 2025 | 2.30 Mn |
| Sep 30, 2025 | 2.45 Mn |
| Jun 30, 2025 | 2.42 Mn |
| Mar 31, 2025 | 1.59 Mn |